Merck & Co., Inc. is a global healthcare leader dedicated to discovering, developing, and delivering innovative medicines and vaccines, with a primary focus on human health pharmaceuticals across oncology, vaccines, and diabetes, alongside a significant animal health division. Operating within the Drug Manufacturers - General industry, Merck leverages strategic collaborations to advance its research and development pipeline. In its most recent reported quarters, Merck demonstrated an upward trend in earnings per share (EPS), with Q3 2025 reporting an actual EPS of $2.58 against an estimate of $2.35, and Q4 2025 reporting $2.04 against an estimate of $2.03. Revenue also saw a significant increase in Q3 2025 to $17.28 billion, and a slight increase in Q4 2025 to $16.40 billion. Comparing the last two reported quarters (Q3 and Q4 2025) to the prior two (Q1 and Q2 2025), EPS growth accelerated, with Q3 2025 showing a notable beat, while Q4 2025 was largely in line with estimates. Revenue growth also showed an acceleration into Q3 2025. Historically, Merck has shown a strong YoY growth trajectory, consistently beating analyst estimates for EPS in the last four reported quarters (Q4 2024 through Q4 2025), with revenue figures generally meeting or exceeding expectations where reported. Recent news highlights Merck's strategic acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, a move expected to close in Q2 2026, and ongoing efforts to enhance employee development through leadership coaching. The company also offers a compelling dividend yield supported by consistent earnings growth. Investors will be watching for the upcoming Q1 2026 earnings report, particularly the actual EPS and revenue figures against estimates, and the continued integration of the Terns Pharmaceuticals acquisition to assess its impact on future growth and pipeline development.
